Furmonertinib qd po
PreclinicalSmall molecule
Furmonertinib qd po is one of 26 small molecule programs targeting Leptomeningeal Metastasis. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Leptomeningeal Metastasis
#DrugCompanyPhaseTrials
1Cytosar
TevaApproved
Trexall
Alnylam PharmaceuticalsApproved
Lenvima
EisaiApproved
Intrathecal Chemotherapy
PPrincess Maxima Center for Pediatric Oncology
Approved
Alimta
EEagle Vision Pharmaceutical Corp.
Phase 2
Folvite
Eli LillyPhase 2
Beyfortus
BeiGenePhase 2
Keytruda
Merck & Co.Phase 2
Decadron
AAspen Global Incorporated
Phase 2
Intrathecal Methotrexate
AmgenPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Leptomeningeal Metastasis1 trial
Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis
Not yet recruiting·GGuangzhou University of Traditional Chinese Medicine·N/A·NCT07348965·42 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Furmonertinib qd po. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details